

1 Evaluation of Commercial Anti-SARS-CoV-2 Neutralizing

2 Antibody Assays in seropositive subjects

3

4 Kahina Saker¹, Bruno Pozzetto², Vanessa Escuret^{1,2}, Virginie Pitiot³, Amélie Massardier-
5 Pilonchéry³, Bouchra Mokdad¹, Carole Langlois-Jacques⁴, Muriel Rabilloud⁴, Dulce
6 Alfaiate³, Nicolas Guibert³, Jean-Baptiste Fassier³, Antonin Bal¹, Sophie Trouillet-Assant^{1,2},
7 Mary-Anne Trabaud¹.

8

9 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
10 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI,
11 Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France

12 ²CIRI- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308,
13 ENS Lyon, Claude Bernard Lyon 1 University, F-69008, Lyon, France.

14 ³Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France

15 ⁴CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive,
16 Equipe Biostatistique-Santé, F-69100, Villeurbanne, France

17

18

19 **ABSTRACT**

20 The virus neutralization test (VNT) is the reference for the assessment of the functional ability
21 of neutralizing antibodies (NAb) to block SARS-CoV-2 entry into cells. New competitive
22 immunoassays measuring antibodies preventing interaction between the spike protein and its
23 cellular receptor are proposed as surrogate VNT (sVNT). We tested three commercial sVNT
24 (a qualitative immunochromatographic test and two quantitative immunoassays named YHLO

25 and TECO) together with a conventional anti-spike IgG assay (bioMérieux) in comparison
26 with an in-house plaque reduction neutralization test (PRNT₅₀) using the original 19A strain
27 and different variants of concern (VOC), on a panel of 306 sera from naturally-infected or
28 vaccinated patients. The qualitative test was rapidly discarded because of poor sensitivity and
29 specificity. Areas under the curve of YHLO and TECO assays were, respectively, 85.83 and
30 84.07 (p-value >0.05) using a positivity threshold of 20 for PRNT₅₀, and 95.63 and 90.35 (p-
31 value =0.02) using a threshold of 80. However, the performances of YHLO and bioMérieux
32 were very close for both thresholds, demonstrating the absence of added value of sVNT
33 compared to a conventional assay for the evaluation of the presence of NAb in seropositive
34 subjects. In addition, the PRNT₅₀ assay showed a reduction of NAb titers towards different
35 VOC in comparison to the 19A strain that could not be appreciated by the commercial tests.
36 Despite the good correlation between the anti-spike antibody titer and the titer of NAb by
37 PRNT₅₀, our results highlight the difficulty to distinguish true NAb among the anti-RBD
38 antibodies with commercial user-friendly immunoassays.

39

40 **Running title:** Evaluation of commercial anti-SARS-CoV-2 sVNT

41 **Key words:** SARS-CoV-2; neutralizing antibodies; commercial tests; surrogate markers of
42 protection; competitive anti-RBD immunoassays.

43

44

45

46 INTRODUCTION

47 Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute
48 respiratory syndrome coronavirus 2 (SARS-CoV-2), and since late 2020, vaccines against
49 SARS-CoV-2 have been available worldwide. In recent months, a large number of
50 commercial immunoassays have been developed for the detection of specific anti-SARS-
51 CoV-2 antibodies (1,2). However, the presence of anti-SARS-CoV-2 antibodies does not
52 indicate whether the antibodies are able to neutralize the virus that has been reported to have a
53 role in the protection from COVID-19 both in animals and humans (3). The gold standard for
54 assessing the ability of antibodies to prevent the virus from entering into susceptible cells is
55 the virus neutralization test (VNT) (4), but it requires a biosafety level 3 laboratory and takes
56 approximately 10 days to complete. This has led to the development of SARS-CoV-2
57 surrogate virus neutralization tests (sVNT) that are more simple and rapid; these are based on
58 the competition between patient antibodies and the angiotensin converting enzyme 2 (ACE2)
59 receptor protein for binding to the spike receptor binding domain (RBD) that mediates the
60 entry of the virus into susceptible cells (5).

61 These competitive immunoassays, which can be conducted using qualitative
62 immunochromatographic cassettes or quantitative automated or manual enzyme-linked
63 immunosorbent assay (ELISA) platforms, allow rapid and easy processing of large numbers
64 of samples in conventional serological laboratories. However, the performance of these newly
65 developed commercial sVNT assays by comparison to classical serological assays detecting
66 anti-RBD IgG and/or to the reference plaque reduction neutralization test 50% (PRNT₅₀)
67 performed with live virus has been poorly evaluated up to now (6–9). Moreover, previous
68 studies have evaluated the specificity using seronegative and/or prepandemic serum which do
69 not inform if commercial sVNT can differentiate serum with or without neutralizing antibody
70 in seropositive samples. The aim of the present study was to evaluate the performance of three

71 commercial sVNT and of a classic anti-RBD IgG assay by comparison to NAb titers
72 measured by a conventional PRNT₅₀ with the original strain (clade 19A) and various clades in
73 seropositive samples.

74

75 **MATERIALS AND METHODS**

76 **Study**

77 This prospective longitudinal cohort study was conducted at the laboratory associated with the
78 national reference center for respiratory viruses (university hospital of Lyon, France).
79 Subjects, (n=306) who were either infected with SARS-CoV-2 (n=246; 83% female; median
80 age 41 [range: 21-66] years) or were scheduled to receive 2 doses of Pfizer BioNtech vaccine
81 (n=31; BNT162b2/BNT162b2; 77% female; median age 41 [range: 26-69] years) or 1 dose of
82 AstraZeneca vaccine followed by 1 dose of Pfizer BioNtech vaccine (n=29;
83 ChAdOx1/BNT162b2; 76% female; median age 35 [range: 21-45] years) were included. For
84 infected patients, a positive RT-PCR test was required; none of them was admitted to hospital.
85 Blood samples were collected 6 months after infection for the convalescent cohort or 4 weeks
86 after the two-dose vaccination for the vaccinated cohort and stored (see supplementary
87 materials and methods).

88

89 **Serological testing**

90 Four assays were used according to the manufacturer's recommendations: Dynamiker
91 Biotechnology (Tianjin, China) SARS-CoV-2 Neutralization Antibody Rapid Test,
92 Schenzhen YHLO Biotechnologies (Schenzen, China) iFlash-2019-nCoV Nab[®], TECO
93 Medical Group (Sissach, Switzerland) SARS-CoV-2 Neutralization Antibody Assay,
94 bioMérieux (Marcy l'Etoile, France) Vidas[®] SARS-CoV-2 IgG assays. The characteristics of
95 the assays are summarized in Table 1. For the present study suppliers kindly provided all

96 serological kits used; there were 81 Dynamiker tests available, and a sufficient number of
97 YHLO, TECO, and bioMérieux kits for all samples tested herein (Supplementary figure S1).
98 YHLO and TECO are quantitative assays, bioMérieux is a semi-quantitative assay and
99 Dynamiker is a qualitative assay. Each assay was compared to the VNT (PRNT₅₀); the latter
100 was used for the detection and titration of neutralizing antibodies, as previously described (4;
101 see supplementary materials and methods). A threshold of 20 and of 80 was used (PRNT₅₀ ≥
102 20/80); the threshold of 20 of the live virus neutralization assay was considered as the
103 detection limit of this assay. Thus, samples with PRNT₅₀ titers below 20 are considered as
104 negative for the presence of neutralizing antibodies. In contrast, the PRNT₅₀ threshold of 80
105 was a cutoff value assumed to discriminate high from low NAb titer.

106 First of all, we compared performance of sVNT assays with VNT (clade 19A) on 81 and 246
107 convalescent samples for the three sVNT and the two quantitative sVNT respectively. As the
108 YHLO assay provided the best results among the investigated sVNT, the added-value of this
109 test compared to a commercial serological assay detecting anti-RBD IgG (bioMérieux) was
110 investigated considering both PRNT₅₀ ≥ 20 and ≥ 80 with clade 19A, and the 246 sera from
111 convalescent individuals and 60 sera collected 1 month post vaccination. In further
112 experiments, we correlated the NAb titers obtained with the YHLO and bioMérieux assays to
113 those of PRNT₅₀ measured against various clades of SARS-CoV-2 on 60 serum specimens
114 collected from vaccinated subjects. Each SARS-CoV-2 isolate used in this study
115 [corresponding to 19A (B38 lineage), alpha (B.1.1.7 lineage), beta (B.1.351 lineage), gamma
116 (P1) and delta (B.1.617.2 lineage) clades] has been sequenced to confirm the characteristic
117 mutations of its viral clade. The sequences of the different viral strains used were deposited
118 on Global Initiative on Sharing Avian Influenza Data (GISAID) [GISAID accession numbers:

119 EPI_ISL_1707038 19A (B.38); EPI_ISL_1707039 Alpha (B.1.1.7); EPI_ISL_768828 Beta
120 (B.1.351); EPI_ISL_1359892 Gamma (P.1); EPI_ISL_1904989; Delta (B.1.617.2)].

121

122 **Statistical analyses**

123 The correlation between Ab concentrations obtained by each assay was investigated using
124 Pearson correlation coefficients and 95% confidence interval [95%CI]. Receiver operating
125 characteristic curves (ROC) were built to estimate the performance of YHLO, TECO, and
126 bioMérieux assays for the detection of the presence of neutralizing antibodies considering the
127 VNT considered as gold standard. Area under the curves (AUC) were compared using the
128 Delong's test. For the YHLO and TECO assays the positive threshold according to the
129 manufacturers' instructions were found to be too low; these were recalculated using the
130 Youden index. Results of various clades were represented with ellipses that show the 95% CIs
131 for different clades schedules, assuming multivariate normal distributions. Statistical analyses
132 were conducted using GraphPad Prism[®] software (version 8; GraphPad software, La Jolla,
133 CA, USA) and R software, version 3.6.1 (R Foundation for Statistical Computing, Vienna,
134 Austria). A p-value <0.05 was considered statistically significant.

135

136 **Ethics statement**

137 Written informed consent was obtained from all participants; ethics approval was obtained
138 from the regional review board for biomedical research in April 2020 (*Comité de Protection*
139 *des Personnes Sud Méditerranée I*, Marseille, France; ID RCB 2020-A00932-37), and the
140 study was registered on ClinicalTrials.gov (NCT04341142) (10).

141

142

143 **RESULTS**

144 **Performance of sVNT**

145 According to the VNT (PRNT₅₀) with clade 19A and the positive threshold of ≥ 20 ,
146 neutralizing antibodies were found in 54.5% (134/246) in the convalescent cohort and 100%
147 (60/60) in the vaccinated cohort; using the positive threshold of ≥ 80 this was the case for
148 10,6% (26/246) and 95% (57/60), respectively. The performance of sVNT assays was
149 estimated among the 81 samples for which data was available using both VNT thresholds
150 [PRNT₅₀ ≥ 20 (59/81) and PRNT₅₀ ≥ 80 (24/81)] and according to the positive threshold
151 indicated by the corresponding manufacturer. The Dynamiker qualitative test exhibited very
152 weak performance both in terms of sensitivity and specificity, and was discarded from the
153 following steps of the evaluation (Table 2).

154 Despite the absence of NAbs detected using PRNT₅₀ ≥ 20 in 112/246 samples and using
155 PRNT₅₀ ≥ 80 in 220/246 samples, the number of samples below the manufacturer positive
156 threshold was 0 with the YHLO assay and 21/246 (8.5%) with the TECO assay. Among the
157 246 samples of convalescent individuals, the median [IQR] titers obtained using the YHLO
158 assay this was 40.69 AU/ml [21.19-156.8] and using the TECO assay was 71.4 IU/ml [36.78-
159 238.3]. Considering the positive threshold of 20 for PRNT₅₀ as the gold standard, the AUC
160 [95%CI] was 0.86 [0.81; 0.90] for the YHLO assay, and 0.83 [0.78; 0.88] for the TECO assay
161 (p-value > 0.05); considering the positive threshold of 80 for PRNT₅₀ as the gold standard, the
162 AUC [95%CI] was 0.96 [0.93; 0.98] for the YHLO assay, and 0.94 [0.90; 0.97] for the TECO
163 assay (p-value=0.02; Figure 1, Table 2). The combination of a good AUC but a very low
164 specificity observed with the positive threshold indicated by the manufacturers led us to

165 determine the best-fit cut-offs for the YHLO and TECO assays using the Youden index.
166 Without weighting for the prevalence of NAb-positive samples, the median [IQR] positive
167 threshold for the YHLO assay this was found to be 28.7 AU/ml [22.6-41.4] considering
168 $\text{PRNT}_{50} \geq 20$ as the gold standard, and 70.1 AU/ml [53.5-89.5] considering $\text{PRNT}_{50} \geq 80$; for
169 the TECO assay was found to be 72.8 IU/ml [53.9-112] considering $\text{PRNT}_{50} \geq 20$ as the gold
170 standard, and 176.3 IU/ml [125-521.2] considering $\text{PRNT}_{50} \geq 80$ (Table 2). Using these
171 optimal thresholds, considering the positive threshold of 20 for PRNT_{50} as the gold standard,
172 the sensitivity [95%CI] and the specificity [95%CI] were 79.10 [62.28; 91.79] and 80.63
173 [65.18; 93.75] respectively for the YHLO assay, and 74.62 [59.7; 85.07] and 83.03 [69.64;
174 94.64] respectively for the TECO assay; considering the positive threshold of 80 for PRNT_{50}
175 as the gold standard the sensitivity [95%CI] and the specificity [95%CI] were 96.15 [92.31;
176 100] and 89.09 [78.63; 94.09] respectively for the YHLO assay, and 92.31 [80.76; 100] and
177 80 [70; 92.27] respectively for the TECO assay (Table 2).

178

179 **Comparison of YHLO assay and bioMérieux anti-RBD assay with regard to PRNT_{50}**

180 The correlation coefficient (ρ [IQR]) between the YHLO assay and the VNT (PRNT_{50}) was
181 0.85 [0.81-0.88] (Figure 2A), and between the VNT (PRNT_{50}) and the bioMérieux assay it
182 was 0.82 [0.78-0.85] (Figure 2B). Considering $\text{PRNT}_{50} \geq 20$ as the gold standard, the AUC
183 [IQR] for the YHLO was 0.90 [0.87-0.94] and for the bioMérieux assay it was 0.88 [0.85-
184 0.92] (p-value > 0.05; Figure 2C); considering $\text{PRNT}_{50} \geq 80$ as the gold standard it was 0.98
185 [0.96-0.99] for the YHLO assay and 0.98 [0.96-0.99] for the bioMérieux assay (p-value >
186 0.05; Figure 2D).

187

188 **Impact of viral strains on Ab neutralizing capacity**

189 Regarding the neutralizing capacity of serum against VOCs, the median fold-reduction in Nab
190 titers varied between 1.3 against alpha strain and 2.7 against beta strain in comparison to 19A
191 strain (Figure 3A and 3B).

192 The Pearson correlation coefficient (ρ [95%CI]) for clades 19A, Alpha, Beta, Gamma and
193 Delta: was of 0.71 [0.26; 0.91], 0.79 [0.43; 0.93], 0.71 [0.23; 0.91], 0.76 [0.36; 0.92] and 0.72
194 [0.29; 0.91] respectively for the YHLO assay, and of 0.86 [0.58; 0.96], 0.96 [0.86; 0.99], 0.83
195 [0.49; 0.95], 0.95 [0.83; 0.98] and 0.88 [0.63; 0.96] respectively for the bioMérieux assay.

196 Despite good correlation between concentrations of anti RBD IgG detected with YHLO or
197 bioMérieux assays and neutralizing antibodies titers against each variant, the same titer of
198 binding Abs overestimates titers of variant Nabs which are lower against the variants than the
199 wild type.

200

201 **DISCUSSION**

202 The performance of the qualitative Dynamiker assay was found to be poor, both in terms of
203 sensitivity and in terms of specificity. The two other quantitative sVNT assays evaluated in
204 the present study were found to be more sensitive but their specificity was extremely low
205 since, at the manufacturers' cutoff, most samples (TECO assay) or all of them (YHLO assay)
206 from convalescent individuals with no detectable NAb using the live virus neutralization
207 assay were positive for NAb with sVNT. It can be postulated that part of the antibodies
208 detected by these ELISA are able to interfere with the interaction between ACE receptor and
209 the viral RBD but not to prevent cell entry of the virus; this may be related to the
210 affinity/avidity of antibodies that is reported to be low after primary infection or first vaccine
211 dose (11,12), and is likely to be even more the case for the population included herein who

212 were sampled 6 months after infection. Despite this low specificity, these assays correlated
213 with the live virus neutralization assay as also found in other studies (5,6,13–15). The low
214 specificity could also be attributed to a lack of sensitivity of live VNT but it is rather unlikely
215 that decreasing the threshold below 20 would be clinically relevant, such low titer having
216 little chance to be protective in vivo (16). In addition, the manufacturer positivity threshold
217 was determined using pre-pandemic serum without any anti SARS-CoV-2 antibodies.
218 Nevertheless, the value of sVNT use is to distinguish antibody with or without neutralizing
219 capacity, and we designed our study to establish this performance using only seropositive
220 samples without presence of Nab to establish specificity for sVNT assays which can
221 explained the low specificity observed in our study.

222 It seems thus preferable to increase the sVNT cutoff to improve specificity, and go closer to
223 the protective threshold. Our data from ROC curves would indicate that, for the detection of
224 NAb, a threshold of 70 IU/ml and 30 AU/ml should be applied for the TECO an YHLO
225 assays, respectively. However, these data have been obtained from infected subjects late after
226 infection, at a time where antibodies are decreasing (17). This could explain the low
227 frequency of sera with detectable NAb using the VNT, and also the discrepancy in terms of
228 specificity between our results and previous ones using samples earlier after infection (18–
229 21). With time, waning of antibodies could have more impact on the blocking of infection
230 than interference with ACE binding. The study of Von Rein et al (22) suggested that the
231 correlation between sVNT and VNT was greater at higher level of neutralization titer and they
232 concluded that sVNT are only useful when inhibition was above 50%, which is more
233 consistent with our data. Most of the previous studies used the cPASS assay from
234 GeneSript, showing the correlation of competitive immunoassay to live VNT, with good
235 sensitivity and specificity compared to VNT (5,6,9,14,15,19,20,22,23). Only a few studies
236 reported results with the TECO (15,20) or YHLO assays (7,8,21). Of note the study of Chan

237 et al (21) found a diagnostic cutoff, with the YHLO assay, of 27,7 AU/ml, which is closed
238 from ours of 30 AU/ml.

239 Other studies have compared VNT and sVNT with assays detecting IgG binding to RBD or S
240 proteins and observed a correlation between them (6,8,9). Fisher et al. (6) found that the
241 correlation between sVNT and antibody binding assay is better for samples with high than
242 low PRNT. Others studies have shown that the correlation between VNT and antibody
243 binding assays was lower than between sVNT and antibody binding assays (9). It remains that
244 high-throughput live virus neutralizing assays is not possible, and for this binding or
245 competitive antibody immunoassays could be used but caution should be taken when
246 interpreting the result, regardless of the assay used. Despite the high performance, based on
247 the AUC of the ROC curve, of the two competitive automated immunoassays evaluated in our
248 study, taking VNT as gold standard, we did not demonstrate any added value of sVNT
249 compared to serological assay detecting anti-RBD IgG for evaluating the presence of Nab in
250 seropositive subjects. These results highlight the difficulty to distinguish the Nab among anti-
251 RBD IgG using a standard immunoassay. This difficulty could be further extrapolated
252 considering the antibodies able to neutralize the SARS-CoV-2 variants. Using serum collected
253 one month post full vaccination in patients with high Nab titers, we confirmed the diminution
254 of Nab titers against different SARS-CoV-2 variant compared to initial strain. Nevertheless,
255 the RBD coated in these competitive sVNT is not adapted to virus evolution and are not able
256 to detect the decrease of NAb titers. To date, VNT remains the only way to detect Nabs
257 against VOC. Taking together, from our data and those previously published, the predictive
258 value of surrogate neutralization assays is still not obvious in all population (infected and/or
259 vaccinated, after priming or boost immunization, early versus late after immunization). In
260 addition, sVNT are not able to predict neutralization of variant, and thus improvements are

261 needed before they can be considered equivalent to VNT to detect NAbs able to protect from
262 infection.

263

264

265 **FUNDING**

266 The respective suppliers kindly provided all the serological kits used in the present study.

267

268 **ACKNOWLEDGMENTS**

269

270 This study was supported by Hospices Civils de Lyon and Fondation des Hospices Civils de
271 Lyon. The respective suppliers kindly provided all the serological kits used. We thank the
272 staff of the occupational health and medicine department of the Hospices Civils de Lyon who
273 contributed to the sample collection. We thank all Clinical Research Associates, for their
274 excellent work. We thank Karima Brahima and all the members of the clinical research
275 department for their reactivity (DRS, Hospices Civils de Lyon). Human biological samples
276 and associated data were obtained from NeuroBioTec (CRB Hospices Civils de Lyon, Lyon
277 France, Biobank BB-0033-00046). We thank all the technicians from the virology laboratory
278 of the Hospices Civils de Lyon who performed the assays on the automated platforms. Lastly,
279 we thank all the healthcare workers for their participation in this clinical study, and Philip
280 Robinson (DRS, Hospices Civils de Lyon) for help in manuscript preparation.

281

282

283

284

285

286

287
288
289
290
291
292
293
294

295 REFERENCES

296

- 297 1. Bal A, Pozzetto B, Trabaud M-A, Escuret V, Rabilloud M, Langlois-Jacques C, et al. Evaluation
298 of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with
299 Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization
300 Test. *Clin Chem*. 2021 Apr 29;67(5):742–52.
- 301 2. Saker K, Escuret V, Pitiot V, Massardier-Pilonchéry A, Paul S, Mokdad B, et al. Evaluation of
302 Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in
303 Vaccinated Health Care Workers. *J Clin Microbiol*. 2022 Jan 19;60(1):e0174621.
- 304 3. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W, et al. Isolation of potent SARS-CoV-2
305 neutralizing antibodies and protection from disease in a small animal model. *Science*. 2020 Aug
306 21;369(6506):956–63.
- 307 4. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigai J, et al. A longitudinal study of SARS-
308 CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-
309 19 severity. *Cellular & Molecular Immunology* [Internet]. 2021 Jan 6 [cited 2021 Jan 11];
310 Available from: <http://www.nature.com/articles/s41423-020-00588-2>
- 311 5. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-
312 binding domain bound to the ACE2 receptor. *Nature*. 2020 May;581(7807):215–20.
- 313 6. Fischer B, Lichtenberg C, Müller L, Timm J, Fischer J, Knabbe C. A combined strategy to detect
314 plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine
315 laboratories. *J Clin Virol*. 2021 Sep 16;144:104984.
- 316 7. Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S, et al. Neutralizing
317 Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
318 *Viruses*. 2021 Jul 14;13(7):1364.
- 319 8. Gillot C, Favresse J, Maloteau V, Dogné J-M, Douxfils J. Dynamics of Neutralizing Antibody
320 Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial
321 Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects. *Viruses*.
322 2021 Nov 22;13(11):2329.
- 323 9. Nandakumar V, Profaizer T, Lozier BK, Elgort MG, Larragoite ET, Williams ESCP, et al.
324 Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute
325 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection
326 Assay and Correlation With Immunoglobulin G Commercial Serology Assays. *Arch Pathol Lab*
327 *Med*. 2021 Oct 1;145(10):1212–20.
- 328 10. Trouillet-Assant S, Albert Vega C, Bal A, Nazare JA, Fascia P, Paul A, et al. Assessment of
329 serological techniques for screening patients for COVID-19 (COVID-SER): a prospective,
330 multicentric study. *BMJ Open*. 2020 Nov 24;10(11):e041268.

- 331 11. Röltgen K, Boyd SD. Antibody and B cell responses to SARS-CoV-2 infection and vaccination.
332 Cell Host Microbe. 2021 Jul 14;29(7):1063–75.
- 333 12. Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de La Selle A, et al. mRNA
334 vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that
335 recognize SARS-CoV-2 variants. Immunity. 2021 Dec 14;54(12):2893-2907.e5.
- 336 13. Cristiano A, Nuccetelli M, Pieri M, Sarubbi S, Pelagalli M, Calugi G, et al. Serological anti-
337 SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-
338 19 paucisymptomatic/symptomatic patients and vaccinated subjects. Int Immunopharmacol.
339 2021 Oct 4;101(Pt B):108215.
- 340 14. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate virus
341 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein
342 interaction. Nat Biotechnol. 2020 Sep;38(9):1073–8.
- 343 15. Krüttgen A, Lauen M, Klingel H, Imöhl M, Kleines M. Two novel SARS-CoV-2 surrogate virus
344 neutralization assays are suitable for assessing successful immunization with mRNA-1273. J
345 Virol Methods. 2021 Sep 23;299:114297.
- 346 16. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against
347 symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021 Nov;27(11):2032–40.
- 348 17. Betton M, Livrozet M, Planas D, Fayol A, Monel B, Védie B, et al. Sera Neutralizing Activities
349 Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months
350 After Hospitalization for Coronavirus Disease 2019. Clin Infect Dis. 2021 Sep 15;73(6):e1337–
351 44.
- 352 18. Tiwari AK, Negi G, Jaiswal RM, Aggarwal G, Yadav N, Kumar V, et al. Correlation of sample-
353 to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization
354 activity: a prospective multi-centric study in India. ISBT Sci Ser. 2021 Jun 28;
- 355 19. Perera RAPM, Ko R, Tsang OTY, Hui DSC, Kwan MYM, Brackman CJ, et al. Evaluation of a
356 SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine,
357 Cat, and Hamster Sera. J Clin Microbiol. 2021 Jan 21;59(2):e02504-20.
- 358 20. Kohmer N, Rühl C, Ciesek S, Rabenau HF. Utility of Different Surrogate Enzyme-Linked
359 Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. J
360 Clin Med. 2021 May 14;10(10):2128.
- 361 21. Chan K-H, Leung K-Y, Zhang R-R, Liu D, Fan Y, Chen H, et al. Performance of a Surrogate
362 SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples.
363 Diagnostics (Basel). 2021 Sep 24;11(10):1757.
- 364 22. von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T, Rodionov RN, et al.
365 Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-
366 19 convalescent plasma. J Virol Methods. 2021 Feb;288:114031.
- 367 23. Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, et al. A New SARS-CoV-
368 2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody
369 Response Detection. J Clin Microbiol. 2021 Mar 19;59(4):e02438-20.

370

371

372

373

374 **Figure 1: Comparison of performance of the two sVNT.** ROC curves were built to
375 estimate the performance of YHLO (in grey) and TECO (in black) assays for detecting the
376 presence of neutralizing antibodies (PRNT₅₀ ≥20 (A)) and high neutralizing antibody titre
377 (PRNT₅₀ ≥80 (B)) from samples of infected patients (n=246).

378

379 **Figure 2: Comparison of performance of the YHLO surrogate quantitative virus**
380 **neutralization test and the bioMérieux anti-RBD IgG assay with reference to the plaque**
381 **reduction neutralization test 50% (PRNT₅₀) from 246 serum specimens collected from**
382 **convalescent patients.** Panels A (YHLO assay) and B (bioMérieux assay) show the strong
383 correlation between each test and PRNT₅₀ (the value of the Spearman correlation coefficient
384 is shown on the upper right part of the panel for each test). ROC curves were built to estimate
385 the performance of the YHLO (in grey) and bioMérieux (in black) assays. Two different
386 positive thresholds were used for detecting neutralizing antibodies by PRNT₅₀: ≥20 (panel C)
387 and ≥80 (panel D). The Delong test was used to compare the areas under the curve (AUC).
388 No statistically significant difference was observed between the two tests for both thresholds.

389


390 **Figure 3: Correlation between the antibody titers obtained with the YHLO test (Panel**
391 **A) or the BioMérieux assay (panel B) and the plaque reduction neutralization test 50%**
392 **(PRNT₅₀).** Ellipses show the 95% CIs for different clades schedules, assuming multivariate

393 normal distributions. Tests were performed with various clades (19A, Alpha, Beta, Gamma
394 and Delta strains) on 60 samples taken from vaccinated individuals.


395

396 **Supplementary figure S1: Study flow diagram.**


(A)




(B)




(A)




(B)



(C)



(D)







Table 1: Characteristics and performance claimed by manufacturer of each assays.

	VNT	sVNT			
		YHLO Biotechnologies	TECO Medical Group	Dynamiker Biotechnology	bioMérieux
	PRNT ₅₀	iFlash	TECO	Dynamiker	Vidas
SARS-CoV-2 detected Ab	Total Ab	IgG	IgG	IgG	IgG
Assay type	Neutralizat ion in cell culture	CLIA	ELISA	Immuno- chromatography	ELFA
Antigen	N/A	RBD	RBD	RBD	RBD
Positive threshold	20 or 80	AU/mL = 10	UI/mL = 20	NA	Index = 1
Manufacturer sensitivity, % [95%CI]	N/A	90	99.03 [94.07; 99.83]	95.74 [85.75; 98.83]	96.6 [82.2; 99.9]
Manufacturer specificity (% [95%CI])	N/A	98	100 [96.68; 100]	99.15 [95.36; 99.85]	99.9 [99.4; 100]

Positivity was established according to manufacturers' instructions. Sensitivity and specificity data were those described in the instruction for utilization sheet from each manufacturer.

Specificity given by manufacturers was obtained from pre pandemic samples.

Abbreviations: Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent assay, CLIA: chemiluminescence immunoassay, ELFA: enzyme-linked fluorescent assay, RBD: receptor binding domain, CI: confidence interval, AU: arbitrary unit, UI: unit international.

Table 2: Performance of the three surrogate viral neutralization test compared to PRNT₅₀ taken as gold standard.

	Dynamiker Biotechnology	YHLO Biotechnologies	TECO Medical Group
	Dynamiker	iFlash	TECO
PRNT ₅₀ ≥20 (n=81)			
Sensitivity, % [95%CI]	49.2 [38.70; 60.10]	100 [95.60; 100]	98.30 [92.80; 99.60]
Specificity, % [95%CI]	77.3 [60.10; 88.50]	0	18.20 [8.40; 34.90]
PRNT ₅₀ ≥80 (n=81)			
Sensitivity, % [95%CI]	66.7 [49.90; 80.10]	100 [89.90; 100]	100 [89.90; 100]
Specificity, % [95%CI]	68.4 [57.70; 77.50]	0	8.80 [4.30; 16.90]
PRNT ₅₀ ≥20 (n=246) AUC, % [IQR]	N/A	85.83 [79.22-88.93]	84.07 [79.22-88.93]
PRNT ₅₀ ≥80 (n=246) AUC, % [IQR]	N/A	95.63 [93.11-98.15]	90.35 [85.56-95.14]
Optimal threshold (PRNT ₅₀ ≥20); n=246	N/A	28.67 [22.58; 41.38] AU/mL	72.82 [53.85; 112] UI/mL
Recalculated sensitivity, % [95%CI]	N/A	79.1 [62.28; 91.79]	74.62 [59.7; 85.07]
Recalculated specificity, % [95%CI]	N/A	80.63 [65.18; 93.75]	83.03 [69.64; 94.64]
Optimal threshold (PRNT ₅₀ ≥80; n=246)	N/A	70.1 [53.46; 89.47] AU/mL	176.25 [124.96; 521.15] UI/mL
Recalculated sensitivity, % [95%CI]	N/A	96.15 [92.31; 100]	92.31 [80.76; 100]
Recalculated specificity, % [95%CI]	N/A	89.09 [78.63; 94.09]	80 [70; 92.27]

IQR: interquartile range, CI: confidence interval, AU: arbitrary unit, UI: unit international.